QT IMAGING HOLDINGS, INC.
No enriched coverage for $QTI in the last 7 days.
No SEC Form 4 filings for $QTI in the last 30 days.
QT IMAGING HOLDINGS, INC. (QTI) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. qti-20260728 false 0001844505 3 Hamilton Landing Suite 160 Novato CA 94949 415 842-7250 QTI 0001844505 2026-07-28 2026-07-28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________ FORM 8-K ________________________________
QT Imaging Holdings, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025, reporting record full-year revenue of $18.9 million, exceeding guidance, and shipping 40 scanners. The company affirmed its 2026 revenue guidance of approximately $39 million, driven by distributor partnerships and the QTI Cloud Platform. Key achievements include FDA clearance for an updated scanner configuration, approval of a new Category III CPT code for its Breast Acoustic CT, and significant financial strengthening through a private placement.
QT Imaging Holdings, Inc. announced the first commercial sale of its QTI Breast Acoustic CT™ System to True Health Center for Functional Medicine, following a strategic distribution partnership. This innovative system aims to improve breast imaging by eliminating compression, radiation, and the need for contrast agents, focusing on patient comfort and safety. The technology, validated by the National Institutes of Health, provides high-quality 3D images and addresses limitations of traditional methods, especially for dense breast tissue.
Recent QTI coverage spans financial news and corporate actions.
The filing is a routine corporate governance update with no new operating or financial guidance.
QT Imaging Holdings reported strong financial results for Q4 and the full year 2025, with record revenue exceeding guidance and key regulatory approvals. The company's positive financial performance and strategic milestones suggest a potential bullish outlook in the near term.
The announcement of the first commercial sale of QTI's Breast Acoustic CT™ System indicates a positive development for the company's growth prospects. The technology's focus on patient comfort and safety could differentiate QTI in the breast imaging market, potentially leading to increased sales and market share.
The release of a new investor presentation and FDA-cleared product may positively influence QTI's valuation over the medium term, though current financial performance remains weak.
The partnership with Olea Medical is expected to strengthen QTI's market position by integrating advanced visualization and AI capabilities, potentially leading to increased adoption and revenue growth.
alphai scores every news story that mentions QTI with an AI model for sentiment and relevance, and aggregates insider trades from QT IMAGING HOLDINGS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
QT IMAGING HOLDINGS, INC. (QTI) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. qti-20260728 false 0001844505 3 Hamilton Landing Suite 160 Novato CA 94949 415 842-7250 QTI 0001844505 2026-07-28 2026-07-28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________ FORM 8-K ________________________________
2 min readQT Imaging Holdings, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025, reporting record full-year revenue of $18.9 million, exceeding guidance, and shipping 40 scanners. The company affirmed its 2026 revenue guidance of approximately $39 million, driven by distributor partnerships and the QTI Cloud Platform. Key achievements include FDA clearance for an updated scanner configuration, approval of a new Category III CPT code for its Breast Acoustic CT, and significant financial strengthening through a private placement.
4 min readQT Imaging Holdings, Inc. announced the first commercial sale of its QTI Breast Acoustic CT™ System to True Health Center for Functional Medicine, following a strategic distribution partnership. This innovative system aims to improve breast imaging by eliminating compression, radiation, and the need for contrast agents, focusing on patient comfort and safety. The technology, validated by the National Institutes of Health, provides high-quality 3D images and addresses limitations of traditional methods, especially for dense breast tissue.
3 min readQT Imaging Holdings (QTI) has released a new investor presentation detailing supplemental product and operational information, including its FDA-cleared QT Breast Scanner. The presentation aims to manage investor expectations by providing regulatory context, financial metrics, and extensive risk disclosures. Spark, TipRanks' AI Analyst, rates QTI as "Neutral" due to weak financial performance tempered by recent positive corporate updates.
2 min readQT Imaging Holdings, Inc. (QTIH) has announced a partnership with Olea Medical to integrate advanced visualization, quantitative analytics, and AI-ready imaging capabilities into QT Imaging's cloud-based SaaS platform. This collaboration aims to enhance clinical interpretation, support research workflows, and enable advanced quantitative imaging analysis, particularly in breast imaging. The integration is expected to strengthen QT Imaging's position by offering a comprehensive, cloud-based platform that combines its acoustic imaging technology with established radiology tools and analytics.
3 min read
